Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Autologous peripheral blood stem cell transplantation for Waldenstrom’s macroglobulinemia

Abstract

We report a 50-year-old male patient with Waldenstrom’s macroglobulinemia poorly responsive to conventional chemotherapy, who went on to receive high-dose melphalan as conditioning before autologous PBSC infusion. Autologous hematopoiesis was reconstituted 5 weeks after transplant. Complete remission was confirmed by blood and marrow examination. The patient remains well at 12 months, with no detectable monoclonal IgM in his serum and absence of plasmacytoid lymphocytes in his marrow. Our results suggest that, at least in this case, high-dose chemotherapy with autologous PBSC support was an effective therapeutic approach for Waldenstrom’s macroglobulinemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, L., Wen, B., Li, H. et al. Autologous peripheral blood stem cell transplantation for Waldenstrom’s macroglobulinemia. Bone Marrow Transplant 24, 929–930 (1999). https://doi.org/10.1038/sj.bmt.1701992

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1701992

Keywords

This article is cited by

Search

Quick links